We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Alpha Cognition Inc. (ACOG - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Alpha Cognition Inc. is a member of our Medical group, which includes 989 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Alpha Cognition Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for ACOG's full-year earnings has moved 49.3% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, ACOG has moved about 58.4% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 3.7% on average. This shows that Alpha Cognition Inc. is outperforming its peers so far this year.
Another stock in the Medical sector, Astellas Pharma Inc. (ALPMY - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 0.9%.
The consensus estimate for Astellas Pharma Inc.'s current year EPS has increased 15.2% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Alpha Cognition Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 497 individual companies and currently sits at #85 in the Zacks Industry Rank. This group has lost an average of 3.4% so far this year, so ACOG is performing better in this area.
Astellas Pharma Inc., however, belongs to the Medical - Drugs industry. Currently, this 155-stock industry is ranked #90. The industry has moved +1.2% so far this year.
Investors with an interest in Medical stocks should continue to track Alpha Cognition Inc. and Astellas Pharma Inc.. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Alpha Cognition Inc. (ACOG - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Alpha Cognition Inc. is a member of our Medical group, which includes 989 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Alpha Cognition Inc. is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for ACOG's full-year earnings has moved 49.3% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, ACOG has moved about 58.4% on a year-to-date basis. Meanwhile, stocks in the Medical group have lost about 3.7% on average. This shows that Alpha Cognition Inc. is outperforming its peers so far this year.
Another stock in the Medical sector, Astellas Pharma Inc. (ALPMY - Free Report) , has outperformed the sector so far this year. The stock's year-to-date return is 0.9%.
The consensus estimate for Astellas Pharma Inc.'s current year EPS has increased 15.2% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, Alpha Cognition Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 497 individual companies and currently sits at #85 in the Zacks Industry Rank. This group has lost an average of 3.4% so far this year, so ACOG is performing better in this area.
Astellas Pharma Inc., however, belongs to the Medical - Drugs industry. Currently, this 155-stock industry is ranked #90. The industry has moved +1.2% so far this year.
Investors with an interest in Medical stocks should continue to track Alpha Cognition Inc. and Astellas Pharma Inc.. These stocks will be looking to continue their solid performance.